Special Issue

Radiomics in Cancer Diagnosis, Prognosis and Treatment

Message from the Guest Editors

This Special Issue relating radiomics discusses innovative approaches in medical diagnostics that exploit the advanced analysis of radiological images, such as images obtained from computed tomography (CT), magnetic resonance imaging (MRI) or other sources of images (e.g., PET). These data are then analyzed using machine learning and artificial intelligence techniques to identify patterns, correlations and predictions. Radiomics therefore offers the possibility of diagnosing diseases early, predicting responses to treatment and identifying subgroups of patients with specific characteristics. This promising approach has the potential to personalize medicine, optimizing clinical decisions through the use of detailed and quantitative data extracted from radiological images. This approach is particularly useful in oncology. A special field of application of growing interest is image-guided radiotherapy, especially after the introduction of hybrid machines (MR-Linacs), among the many different oncological clinical contexts radiomics can be applied in. Radiomics may be used in conjunction with the genetic profiling of tumors (radiogenomics) to further personalize treatments.

Guest Editors

Prof. Dr. Stefano Maria Magrini

Prof. Dr. Filippo Alongi

Prof. Dr. Michela Buglione

Prof. Dr. Davide Farina

Dr. Luigi Spiazzi

Deadline for manuscript submissions

closed (30 June 2025)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/192400

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)